



GLOBAL SCIENCES

CSE:CBDN

OTCPINK:CBDNF

FRANKFURT:GS3



aethics™



resinosa



FORWARD LOOKING STATEMENT

Forward-looking information contained in this presentation and other forward looking information are based on our opinions, estimates and **assumptions** in light of our experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we currently believe are appropriate and reasonable in the circumstances. Despite a careful process to prepare and review the forward-looking information, there can be no assurance that the underlying opinions, estimates and assumptions are an actual representation of the future final results. For further details on the forward looking information included in this presentation, see “Forward- Looking Statements” which can be viewed at [www. SEDAR.com](http://www.SEDAR.com).

Although we have attempted to identify important risk factors that could cause actual results to differ materially from those contained in forward-looking information in this presentation, there may be other risk factors not presently known to us or that we presently believe are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information in this presentation. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information, which speaks only as of the date made.



OUR VISION

WHO WE ARE

CBD Global Sciences is a vertically integrated hemp-based CBD manufacturing and branding company which currently offers multiple product categories, private label manufacturing, retail sales, distribution and fulfillment. Our focus is on **industry consolidation**, creation of points of distribution for our products and our competitors products which in turn creates opportunities for manufacturing for those companies. A value proposition that makes sense for both our company and our competitors.






OUR VALUE PROPOSITION

How We are Creating Revenue Streams for Our Company and Our Competitors

Addressing three specific needs in the CBD Industry:

- How does a CBD company get its brand to market?
- Once demand is created for that product, how does a CBD company scale where manufacturing of CBD products lacks compliance and is difficult to find?
- How does a private CBD company create an exit strategy?





OUR VALUE PROPOSITION

How We are Creating Revenue Streams for Our Company and Our Competitors

Addressing three specific needs in the CBD Industry:

- With Legacy we created points of distribution to assist CBD Brands in penetrating market and sell products across 5000+ established relationships.
- From those distribution agreements we've created a manufacturing opportunity for our manufacturing division.
- We've created a selective way for profitable private CBD companies to consolidate into our PUBCO that creates a roadmap for the owners to see an profitable exit strategy within 24-36 months.





WHY CBD GLOBAL SCIENCES

Key factors that are allowing our company to acquire other profitable companies and assist its competitors

01.

Debt restructuring activity over the past 18 months has reduced liabilities on the balance sheet by 75%.

02.

Modified our focus to industry consolidation activity with interest in profitable companies that need to consolidate into a public company to see scalable and sustainable growth.

03.

Creation of Legacy Distribution enables CBDGS to create a value proposition that is difficult for competitors to refuse. We help them achieve market penetration and brand awareness.

04.

Acquisition of the Resinosa established a road map on how to consolidate with a winning proposition for both companies. It also creates a revenue stream for The PUBCO as we assist companies to market by providing manufacturing opportunities as they scale their business.



TIMELINE TO PUT WINS ON THE BOARD

We are in it ...TO WIN IT!

01.

Our goal for CBD Global Sciences is to be the first CBD company to pay its investors a dividend.

02.

Expectation is to see revenues from work that is already being done is April 2022 where our Q4 results will show significant revenues improvement under this new model.

03.

First acquisition achieved in early Q4 of 2021 which framed out the process to acquire profitable companies with ZERO cash up front. CBDGS currently has three additional 'value targets' that it has engaged, all profitable well run private companies, diamonds in the rough.



04.

Creation of Legacy Distribution enables CBDGS to see and study a multitude of profitable CBD and non-CBD companies at various stages of development, all interested in our value proposition in various levels of participation.





OUR SHARE STRUCTURE



Common Shares Outstanding

34.5 Million Shares

Insider Share Position

28%

Reserved for Issuance

80.1 Million

Public Float

28 Million Shares



source: www.thecse.com



CBD GLOBAL SCIENCES INC.

CSE:CBDN

OTCPINK:CBDNF

FRANKFURT:GS3

Contact Information:

Brad Wyatt

brad.wyatt@aethics.com

www.cbdglobalsciences.com

info@cbdglobalsciences.com